Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Phenotypic Spectrum and Epigenomewide Profiling of SETD1B-Related Neurodevelopmental Disorder

EF 2023-24

Résumé
Among the childhood epilepsy disorders, SETD1B-related neurodevelopmental disorder (SETD1B-NDD) is a recently-described genetic disease that also causes autism and intellectual disability. Dr. William Gibson and his team established SETD1B-NDD as its own disorder by reporting 4 unrelated patients with Pathogenic variants (harmful changes) in the SETD1B gene. To provide better clinical care and more sensitive diagnostic measures to patients, we aim to uncover as-yet-unknown clinical signs and symptoms of the disease, and figure out the consequences of specific mutations in the SETD1B gene. We will do this using our new registry of rare epigenetic diseases, which has been enrolling patients in British Columbia, Canada and internationally for 12 months. Analysis of data collected from physician-completed and family-completed surveys in the registry will give us new insights into how mutations in this gene affect the development of kids’ brains. Furthermore, the inclusion of adult patients worldwide will help us assess long-term complications and outcomes, which will in turn help us design appropriate medical surveillance plans for children. In addition to expanding our knowledge of Pathogenic variants in SETD1B, the project will address a subset of patients who have Variants of Unknown Significance (VoUS) and cannot yet be formally diagnosed with SETD1B-NDD. In collaboration with Canada’s Michael Smith Genome Sciences Centre (GSC), we are developing a diagnostic method called epigenomewide profiling to distinguish VoUS from harmful variants in SETD1B. This method will be useful diagnostically in children with neurodevelopmental delays and/or epilepsy who are unsolved by other diagnostic tests.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506575
Name
Yu Crystal A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Phenotypic Spectrum and Epigenomewide Profiling of SETD1B-Related Neurodevelopmental Disorder
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Compass; Developmental Delay; Epigenetics; Epigenomewide Profile; Epilepsy; Histone 3 Lysine 4 Methylation; Intellectual Disability; Medical Genetics; Neurodevelopmental Disorder; Rare Genetic Disorders
Abstract
Among the childhood epilepsy disorders, SETD1B-related neurodevelopmental disorder (SETD1B-NDD) is a recently-described genetic disease that also causes autism and intellectual disability. Dr. William Gibson and his team established SETD1B-NDD as its own disorder by reporting 4 unrelated patients with Pathogenic variants (harmful changes) in the SETD1B gene. To provide better clinical care and more sensitive diagnostic measures to patients, we aim to uncover as-yet-unknown clinical signs and symptoms of the disease, and figure out the consequences of specific mutations in the SETD1B gene. We will do this using our new registry of rare epigenetic diseases, which has been enrolling patients in British Columbia, Canada and internationally for 12 months. Analysis of data collected from physician-completed and family-completed surveys in the registry will give us new insights into how mutations in this gene affect the development of kids’ brains. Furthermore, the inclusion of adult patients worldwide will help us assess long-term complications and outcomes, which will in turn help us design appropriate medical surveillance plans for children. In addition to expanding our knowledge of Pathogenic variants in SETD1B, the project will address a subset of patients who have Variants of Unknown Significance (VoUS) and cannot yet be formally diagnosed with SETD1B-NDD. In collaboration with Canada’s Michael Smith Genome Sciences Centre (GSC), we are developing a diagnostic method called epigenomewide profiling to distinguish VoUS from harmful variants in SETD1B. This method will be useful diagnostically in children with neurodevelopmental delays and/or epilepsy who are unsolved by other diagnostic tests.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yu, Crystal A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~